Regeneron Pharmaceuticals (REGN), an industry leader in the bio-tech market, faced both opportunities and challenges over the past period. Various investment firms, including
Fifth Third Bancorp and
Handelsbanken Fonder AB, have sold REGN shares, while others, like
Harbor Capital Advisors and
RMR Wealth Builders, have invested heavily. Despite downgrading the company’s stock due to a failed COPD drug test with Sanofi, analysts at
JP Morgan considered the selloff excessive. REGN also came into focus for adopting
innovative technology to hasten drug discovery and was chosen as a backup bidder in the
23andMe asset sale. Major investments, from firms like
NorthCrest Asset Management and investment gains from products like Dupixent and EYLEA HD, underscore the company's strong position. In addition, the company reported encouraging initial data on its trial for a
multiple myeloma drug. There are diverging views on the stock’s value, with some analysts considering it undervalued, whereas others, like UBS and Morgan Stanley, have lowered price targets.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 25 Mar 2025 07:00:00 GMT to Sat, 14 Jun 2025 10:55:02 GMT -
Rating 3
- Innovation 7
- Information 6
- Rumor 2
